clinical trial · NCT03993379
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Solid TumorUnresectable or Metastatic MelanomaCX-072Ipilimumab
brief summary
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
started
Nov 20, 2019
primary completion
May 21, 2020
completion
May 21, 2020
last updated
Dec 26, 2025
official title
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol